Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug‐drug interactions
Elise J. Smolders, Floor A. C. Berden, Clara TMM de Kanter, et al.
United European Gastroenterology Journal (2016) Vol. 5, Iss. 5, pp. 648-657
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Loss to follow‐up in the hepatitis C care cascade: A substantial problem but opportunity for micro‐elimination
Marleen van Dijk, Joost P.H. Drenth
Journal of Viral Hepatitis (2020) Vol. 27, Iss. 12, pp. 1270-1283
Open Access | Times Cited: 47
Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants
Xiao‐Jian Zhou, Gaetano Morelli, Maureen Montrond, et al.
Clinical Pharmacology in Drug Development (2025)
Open Access
Vitamin C reduces gastric pH in pharmacologically induced hypochlorhydria: a potential approach for mitigating pH-dependent drug-drug interactions of weak-base drugs
Hala M. Fadda, Andrea Shin, Mohammed Rayyan Waseem, et al.
Journal of Pharmaceutical Sciences (2025), pp. 103809-103809
Closed Access
Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations
Rianne A. Weersink, David M. Burger, Kelly L. Hayward, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 16, Iss. 1, pp. 45-57
Open Access | Times Cited: 34
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection
Steven L. Flamm, K. Rajender Reddy, Neddie Zadeikis, et al.
Clinical Gastroenterology and Hepatology (2018) Vol. 17, Iss. 3, pp. 527-535.e6
Open Access | Times Cited: 21
Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
Lu-Hua Gao, Qing‐He Nie, X. Zhao
International Journal of General Medicine (2021) Vol. Volume 14, pp. 289-301
Open Access | Times Cited: 16
Cardiovascular Risk Management and Hepatitis C: Combining Drugs
Elise J. Smolders, Peter G. J. ter Horst, Sharon Wolters, et al.
Clinical Pharmacokinetics (2018) Vol. 58, Iss. 5, pp. 565-592
Open Access | Times Cited: 20
The potential hepatoprotective effect of metformin in hepatitis C virus‐infected adolescent patients with beta thalassemia major: Randomised clinical trial
Mona S. Abdel Monem, Samar Farid, Maggie Abbassi, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 6
Closed Access | Times Cited: 13
Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
Jenny Hong, Robert C. Wright, N. Partovi, et al.
Journal of Clinical and Translational Hepatology (2020) Vol. 8, Iss. 3, pp. 1-14
Open Access | Times Cited: 13
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
Xiaoqing Liu, Peng Hu
Journal of Clinical and Translational Hepatology (2021) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 12
HCV antiviral drugs have the potential to adversely perturb the maternal-fetal communication axis through inhibition of CYP3A7 DHEA-S oxidation
Hannah M. Work, John C. Hackett, Jed N. Lampe
Drug Metabolism and Disposition (2024) Vol. 52, Iss. 6, pp. 516-525
Open Access | Times Cited: 1
Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir
Tony K. L. Kiang
European Journal of Drug Metabolism and Pharmacokinetics (2018) Vol. 43, Iss. 5, pp. 509-531
Closed Access | Times Cited: 9
Prevalence of the potential drug–drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Lizasoaín, et al.
Gastroenterología y Hepatología (English Edition) (2019) Vol. 42, Iss. 8, pp. 465-475
Closed Access | Times Cited: 9
Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis
Armand Abergel, Tarik Asselah, A. Mallat, et al.
Liver International (2020) Vol. 40, Iss. 8, pp. 1853-1859
Closed Access | Times Cited: 9
Concomitant Intake of Coca‐Cola to Manage the Drug–Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers
Minou van Seyen, Angela Colbers, Evertine J. Abbink, et al.
Clinical Pharmacology & Therapeutics (2019) Vol. 106, Iss. 5, pp. 1093-1098
Open Access | Times Cited: 8
Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Lizasoaín, et al.
Gastroenterología y Hepatología (2019) Vol. 42, Iss. 8, pp. 465-475
Closed Access | Times Cited: 8
Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
Jung Wha Chung, Hwa Young Choi, Moran Ki, et al.
Gut and Liver (2020) Vol. 15, Iss. 2, pp. 295-306
Open Access | Times Cited: 8
Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
Kuo‐Chih Tseng, Meng‐Hsuan Kuo, Chih‐Wei Tseng, et al.
Tzu Chi Medical Journal (2020) Vol. 32, Iss. 4, pp. 331-331
Open Access | Times Cited: 6
Efficacy and Safety of Elbasvir‐Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real‐Life Clinical Practice
Benedetto Caroleo, Lidia Colangelo, Maria Perticone, et al.
The Journal of Clinical Pharmacology (2018) Vol. 58, Iss. 10, pp. 1248-1253
Closed Access | Times Cited: 3
Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus
Luis Margusino‐Framiñán, Purificación Cid‐Silva, Víctor Giménez‐Arufe, et al.
European Journal of Hospital Pharmacy (2019) Vol. 28, Iss. 1, pp. 16-21
Open Access | Times Cited: 3
An Interaction Between Glecaprevir, Pibrentasvir, and Colchicine Causing Rhabdomyolysis in a Patient With Chronic Renal Disease
Dawn S. Harrison, Jane Giang, Jama M. Darling
Clinical Liver Disease (2020) Vol. 15, Iss. 1, pp. 17-20
Open Access | Times Cited: 2
Clinical Experience of Patients With Hepatitis C Treated With Direct-Acting Antivirals After Heart Transplantation
You-Min Lu, Wei-Ling Yang, Chung‐Yi Chang, et al.
Transplantation Proceedings (2020) Vol. 53, Iss. 2, pp. 665-672
Closed Access | Times Cited: 2
Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium : an observational study
Stefan Bourgeois, JP Mulkay, Mike Cool, et al.
Acta Gastro Enterologica Belgica (2021) Vol. 84, Iss. 1, pp. 33-41
Open Access | Times Cited: 2
If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs
Daan W. Von den Hoff, Floor A. C. Berden, Arnt Schellekens
United European Gastroenterology Journal (2021) Vol. 9, Iss. 10, pp. 1101-1102
Open Access | Times Cited: 2
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study
V. Calvaruso, Salvatore Petta, Donatella Ferraro, et al.
Digestive and Liver Disease (2021) Vol. 54, Iss. 8, pp. 1117-1121
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top